Cell therapy method for the treatment of tumors
OwnerDidier J. Leturcq, Ann M. Moriarty +3inventors
InventorsDidier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richard
Life of this patent
Estimating the term…
Loading patent…
OwnerDidier J. Leturcq, Ann M. Moriarty +3inventors
InventorsDidier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richard
Estimating the term…
T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCS; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.
A method for treating a viral infection in a subject comprising:
A method for treating a subject with melanoma, comprising the steps of:
Dependencies are inferred from the claim text.